CLEVELAND, April 28, 2016 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company will showcase its MRIdian System, the world's first and only clinical MRI-guided radiation therapy system, at ESTRO 35, the annual meeting of the European Society for Radiotherapy and Oncology, being held April 29 to May 3, 2016 in Turin, Italy.
On Monday, May 2, 2016 from 1:25 p.m. to 2:25 p.m. Central European Time in Room 2, ViewRay will host a Symposium titled "Adaptive Therapy and Beyond: Multi-center Experience with MRI-Guided Radiation Therapy", which will feature presentations from faculty at four MRIdian centers: VU University Medical Center in Amsterdam; Jonsson Comprehensive Cancer Center (UCLA Health); Siteman Cancer Center (Washington University/Barnes-Jewish Hospital); and Carbone Cancer Center (University of Wisconsin).
MRIdian will be the subject of five presentations as part of ESTRO's Scientific Program covering clinical experience with lung, liver and rectal cancers. These talks focus on the advantages MRI-guided radiation therapy brings to aligning, adapting and tracking in real-time during treatment. A full list of MRIdian-focused Scientific Program presentations is available at http://www.viewray.com/estro_2016.htm.
Visitors to ViewRay's booth #5700 can also learn more about the company's technology in development, the MRIdian Linac, which is currently available for non-clinical research use only. Visitors can see how ViewRay's patented magnetic shielding and radiofrequency cloaking technologies enable a compact linac design that maintains the existing footprint to fit into most existing vaults. The combination of linac technology with ViewRay's patent pending double focused multi-leaf collimator is designed to provide ultra-sharp beams for high precision treatments. ViewRay expects to apply for FDA clearance and CE Mark for the MRIdian Linac in the second half of 2016 and to offer the linac technology as an upgrade for existing systems and as an option for new system installations.
Also in ViewRay's booth attendees can hear firsthand clinical experience from three MRIdian users who will present on topics including MRIdian's soft-tissue image quality and plan reoptimization for on-table adaptive treatments. Presentations will take place at various times on Saturday, Sunday and Monday. A detailed schedule of presenters, dates and times is available at http://www.viewray.com/estro_2016.htm.
"We believe the ability to image with MRI while radiation beams are being delivered and to adapt plans while the patient is on the table are two of the most promising advances in radiation oncology. Both are a reality today with MRIdian," said Chris A. Raanes, ViewRay president and CEO. "We're excited that this year's ESTRO attendees have a number of opportunities to hear about transformative clinical experiences from a growing body of MRIdian users."
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to ViewRay's application for FDA clearance and CE Mark for the MRIdian Linac, and the symposium and other presentations at ESTRO 35. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the MRIdian linac, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
SOURCE ViewRay Incorporated